Skip to main content
. 2022 Aug 18;6(16):4821–4830. doi: 10.1182/bloodadvances.2022007474

Table 4.

CAR T-cell outcomes

CAR T-cell outcomes Patients N = 280
Follow up time, median days (range) 218 (7-1340)
Disease progression, n (%) 122 (44)
Days to progression, median (range) 83 (7-742)
Death, n (%) 68 (24)
Days to death, median (range) 150 (7-664)
ANC <1000 after d 30 116 (41)
IgG <400 after d 30 99 (35)
IVIG administration after d 30 111 (40)
CD4 T-cell count <200 after d 30 55 (20)

IVIG, IV immunoglobulin G.